Mesothelial cyst of the pulmonary ligament: An uncommon lesion
Dear Editor,
The importance of a thorough knowledge of thoracic anatomy is timeless. Lung and pleural anatomy continues to be a subject for study nowadays, not only due to the greater spatial resolution of newer diagnostic studies, such as bronchoscopy, computed tomography and magnetic resonance, but also because of advances in thoracic surgery.
The pulmonary ligaments are among the lesser known structures of the thoracic anatomy. The radiological importance of the pulmonary ligament was first described in 1966 by Rabinowitz and Wolfe, 1 and only very few reports or series have been found which describe the radiological findings of pathologic processes within the pulmonary ligaments. 1---6 This ligament, just like any other thoracic anatomical structure can be affected by non-infectious or infectious inflammatory processes, tumors, congenital or developmental abnormalities and scarring. 2---6 There are only a few reports in the literature which mention this anatomical structure and different pathological process.
The following case description of a cystic lesion within the right pulmonary ligament illustrates the anatomy and pathology of this structure:
A 75-year-old woman diagnosed with a pharyngeal cancer was referred for magnetic resonance imaging of the neck and a computed tomography (CT) of the chest and upper abdomen. The enhanced CT chest demonstrated an incidental tubular cystic lesion, oriented parallel to the mediastinum, within the right pulmonary ligament, extending from the level just caudal to the right inferior pulmonary vein down to the diaphragm. This lesion measured 5.5 cm × 2.7 cm × 1.8 cm and showed homogeneous density, mean attenuation value = −3.92 Hounsfield Units (HU). This lesion was separated from pericardium by a layer of fat. The lesion was followed up and remained stable in size and shape for 4 years, as per the comparison with a previous CT scan. The appearance on axial, coronal and sagittal planes confirmed that the cyst was within the pulmonary ligament ( Figs. 1 and 2 ). The cystic lesion also had no depression of the hilar structures or elevation or blurring of the diaphragm. So the non-symptomatic clinical setting alongside with the anatomical landmarks described and the lack of change in size/configuration during these years supported the diagnosis of a mesothelial cyst of the pulmonary ligament.
This case under discussion provides a very good illustration of the anatomical concepts that define the pulmonary ligament as double layer of pleura that drapes caudally from the lung root and ropes the medial aspect of the lower lobes of the lung to the mediastinum. 2 On the left, the ligament is medial and adjacent to the esophagus and is bounded posteriorly by the descending aorta. On the right, the ligament is posterior to the inferior vena cava and anterior to the azygos vein.
2---4 Each ligament contains connective tissue which blends with the hilar connective tissue superiorly, and with mediastinal connective tissue medially. Laterally, the connective tissue of the ligaments is continuous with the interstitial connective tissue of the lung.
2---4
On CT scans normal ligament can be visible as a thin linear density arising from the mediastinum below the hilar structures on lung window. 3 Few reports in the literature have described air within the pulmonary ligament, post-traumatic or from ruptured Moreover, around 11---18% of mediastinal masses are related to the foregut developmental abnormalities, including bronchogenic or duplication cysts. The phase of the embryonic development during which the error occurs seems to play a role in the location and type of malformation. Foregut cysts arise late in the gestation. The age of presentation may vary from prenatal to late adulthood. Almost a quarter of the patients with foregut cysts are asymptomatic. 7 The presented clinical case therefore illustrates a rare but typical cystic lesion, probable arising from developmental error within the pulmonary ligament.
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High-flow nasal oxygen is not an oxygen therapy device
Traditionally the oxygen therapy systems have been classified as low and high flow. Low-flow systems do not provide all the inspiratory flow demanded by the patient; do not ensure stable levels of FiO 2 and it is not possible to control the temperature and moisture of inspired gas. The low flow oxygen system most widely used is the nasal prongs. By contrast, high flow systems are able to provide the entire atmosphere breathed by the patient and do ensure a stable FiO 2 and it is possible to control the temperature and moisture of the inspired gas. The typical high flow oxygen system is the venturi mask. 1 In recent years, a new way of supplying patients with oxygen has appeared which in our opinion has been incorrectly called high-flow nasal cannula oxygen therapy (HFNC). 2 This therapeutic approach has a lot of physiological effects which makes it a really active treatment for patients with both acute and chronic respiratory failure; it is more than a simple oxygen delivery system. Several studies have shown that HFNC generates a low level of positive airway pressure, improves oxygenation, increases the end-expiratory lung volume, reduces airway resistance, increases functional residual capacity and alveolar recruitment and flushes nasopharyngeal dead space, thus helping to decrease the work of breathing. There is a better control of FiO 2 and the gas humidification ensures better patient tolerance and comfort. Due to a better mucociliary clearance, pulmonary defense mechanisms are restored. 3 Many of these effects are similar to those produced by non-invasive ventilation. Several studies have shown its utility in patients with acute hypoxemic respiratory failure, in the post-extubation period, in palliative care, in patients with acute heart failure, in chronic airway diseases and its indications are still rising. It is used in critical care areas, in the emergency department, in wards and it is being used at home in COPD patients. 4, 5 As we can see, oxygen plays a secondary role in this treatment. The name of high-flow oxygen therapy is confusing. Although the efficacy of improvement in respiratory gas exchange and effectiveness in outcomes has been demonstrated, we have not fully understood the main pathophysiological principles of this therapy. The role and importance of each of the mechanisms related to the high-flow therapy, the end expiratory positive pressure, the flushing of nasopharingeal dead space or the humidification and warming of the inspired air, has not been clarified yet. Up to now, we have not been able to identify the functional significance of each of the three mechanisms, maybe this is a question that will never be answered because in different clinical situations the relevance of these potencial mechanisms changes. What is clear is that high-flow is not an oxygen therapy device. Most international groups working in this field use the term ''Nasal High Flow'' avoiding the term ''oxygen'' in its definition.
We think such an active treatment should have a name that reflects the effects of the treatment better, in order to avoid confusion. And that deserves some careful reflection. High-flow can be applied through nasal cannula or tracheostomy, so the term ''nasal'' should not be part of the name. Perhaps the name ''Active High Flow'' would be more accurate so as to clearly distinguish it from the conventional or ''passive'' high flow like the venturi system. The Venturi system is usually administered by mask and high flow by cannula, which could be another distinguishing feature. Taking into account the different but also relevant effects of the therapy, we might ask why not include the term ''humidification'' or ''heating'' to the words ''high flow''. The positive expiratory pressure effect could probably be more interesting to incorporate into the name. Although the pressure achieved is highly dependent on the individual patient and the interface used, is low in absolute value and, above all, not determined by the prescribed parameters of the equipment, we do have quite a lot about its relevance. Certainly, this therapy has demonstrated that can be useful in treating sleep apnea syndrome. 6, 7 Its effect on alveolar recruitment has been clearly shown by Corley et al. 8 Roca et al. 9 have also indirectly demonstrated the positive intrathoracic pressure reached with the HFNC, showing a reduction greater than 20% in the estimated inspiratory collapse of the inferior vena cava from baseline. Perhaps the provocative name of ''High-flow positive pressure'' would better define a treatment that gives the patient a high flow of heated and wet gas, with a level of positive pressure, and a controlled FiO 2 . Anyway, the name of high-flow oxygen therapy would be restricted to the classical high flow system such as the venturi system. We think that a consensus on a more precise name is required.
